[One-year results after Cypass implantation]

Area of Science:

• Ophthalmology
• Medical Devices
• Glaucoma Treatment

Background:

• The Cypass Microstent is a biocompatible implant designed for the suprachoroidal space.
• It aims to enhance aqueous humor outflow through the uveoscleral pathway.

Purpose of the Study:

• To evaluate the efficacy of the Cypass Microstent in reducing intraocular pressure (IOP) in patients with mild to moderate glaucoma.
• To compare outcomes in different patient groups based on prior surgical history and concurrent procedures.

Main Methods:

• A retrospective study involving 162 patients (220 eyes) with mild to moderate glaucoma.
• Patients were divided into three groups: pseudophakic with Cypass, Cypass with phacoemulsification/IOL, and those with prior multiple eye surgeries.
• Follow-up was conducted over a 1-year period.

Main Results:

• Mean IOP reduction was 11.7% in group 1 (pseudophakic) and 13.4% in group 2 (Phako/HKL) after 12 months.
• Group 3 (multiple prior surgeries) showed a non-significant IOP reduction of 11.2%.
• Additional interventions were required in 20.5% of cases to achieve target IOP.

Conclusions:

• The Cypass Microstent demonstrated similar efficacy in reducing IOP in pseudophakic patients and those undergoing combined phacoemulsification/IOL implantation.
• Both groups also showed a reduction in the use of topical glaucoma medications.
• The implant was less effective in patients with a history of multiple ocular surgeries.